ONERA-HEALTH
Onera Health announced today the introduction of its first Onera Biomedical-Lab-on-Chip™. The biomedical sensor system-on-chip acquires and processes multiple biosignals and is designed for a broad range of wearable health applications and devices, offering many solutions and opportunities for innovation in the medical, wellness and fitness space.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220103005188/en/
"We are thrilled to introduce Onera Biomedical-Lab-on-Chip™ in the lead-up to CES 2022 in Las Vegas this week. It's the perfect opportunity to showcase our chip to the wearables ecosystem! Our highly integrated and comprehensive biosignal sensor hub is a unique solution that promises to revolutionize this competitive field. It combines clinical-grade physiological measurements and analysis with ultra-low-power consumption, enabling the development of miniaturized and high-quality wearable devices. Launching this powerful chip as a stand-alone product within our portfolio, not just as part of our innovative Onera diagnostic and monitoring solutions, is yet another exciting step for our company", explains Ruben de Francisco, Founder and CEO of Onera.
The Dutch-American company leveraged from its deep tech roots and close partnership with imec, a world-leading research and innovation hub in nanoelectronics and digital technologies, with the development of the ultra-low-power biosignal chip.
“Seeing Onera bring this ground-breaking system-on-chip to the market is what imec’s unique experience in semiconductor devices for MedTech applications, and our imec ecosystem, is all about - enabling nano- and digital technology innovation that promises a significant impact on the quality of life”, added Rudi Cartuyvels, COO of imec.
Onera Biomedical-Lab-on-Chip™ is a multi-channel sensor readout system with integrated data processing, power management, and interfacing features. It offers a wide range of on-chip biomedical sensor readouts, including 10 readouts for ExG, covering EEG, ECG, EMG, and EOG, 2 bioimpedance readouts, and 2 readouts for photoplethysmography. The data can be processed by on-chip digital filters and accelerators, supported by a powerful ARM Cortex M4f. The chip features several standard wired interfaces such as UART, SPI, I2C, and I2S. The chip fully operates on a single power source which can be anything between 0.8V and 3.6V, since power management is also integrated on-chip. In addition, a large amount of SRAM and embedded FLASH is available, supporting the large number of data streams with accurate data-synchronization as an essential feature.
To support the development and transition to commercialization of Onera’s products, the company has ramped-up hiring recently, including adding to its strong leadership team.
From the 5th to the 8th of January 2022, Onera Health exhibits its Onera STS I Polysomnography Solution and its Onera Biomedical-Lab-on-Chip™ at CES 2022 in Las Vegas, booth 8570 in the LVCC - North Hall.
About Onera
Onera Health is a leader in transforming diagnostics and monitoring. Their breakthrough products and technologies are poised to help millions of people struggling with health ailments and chronic conditions in a variety of medical fields, including sleep, neuro, cardiac and respiratory care, ultimately improving the health and quality of life for patients around the world. The company’s innovative solutions provide comprehensive physiological and health-related data to physicians in a variety of clinical and non-clinical environments to optimize patient care and reduce healthcare costs. Onera has offices in the Netherlands and the US. For more information, go to www.onerahealth.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220103005188/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Volante Technologies Customers Successfully Navigate Critical Regulatory Deadlines for EU SEPA Instant and Global SWIFT Cross-Border Payments16.12.2025 10:00:00 CET | Press release
PaaS leader ensures seamless migrations and uninterrupted payment operations Volante Technologies, the global leader in Payments as a Service (PaaS), today announced it has successfully upgraded its clients to meet the latest SEPA Instant Payments Regulation (IPR) and SWIFT SRG 2025 mandate, which came into effect October 9th and November 22nd, 2025, respectively. This announcement follows the major FedISO upgrade in July, which shifted trillions of dollars in payments to the new ISO 20022 messaging format. SEPA IPR is a significant European milestone, requiring payments to be made within 10 seconds and at any time of day, throughout the year. Adoption was mandatory and Eurozone banks were compelled to meet strict deadlines, with January 9th, 2025 the deadline for receiving incoming instant payments and October 9th the deadline for sending outgoing instant payments. The latest deadline impacted more than 700 banks across Europe, with non-compliance penalties reaching at least 10% of an
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release
RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 07:00:00 CET | Press release
Leading encryption provider deepens commitment to European financial sector with rigorous new supplier qualification, building on existing UK & Ireland certification. Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It p
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 03:00:00 CET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom